Please ensure Javascript is enabled for purposes of website accessibility

5-Star Stocks Poised to Pop: Harvard Bioscience

By Brian D. Pacampara, CFA - Updated Apr 6, 2017 at 10:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Market-trouncing returns could be written in these five stars.

Based on the aggregated intelligence of 170,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical instruments specialist Harvard Bioscience (Nasdaq: HBIO) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Harvard Bioscience's business and see what CAPS investors are saying about the stock right now.

Harvard Bioscience facts

Headquarters (Founded)

Holliston, Mass. (1901)

Market Cap

$168.6 million


Life sciences tools and services

Trailing-12-Month Revenue

$108.2 million


Chairman/CEO Chane Graziano

CFO Thomas McNaughton

Return on Equity (Average, Past 3 Years)



$19.7 million / $18 million


Becton Dickinson (NYSE: BDX)

Bio-Rad Laboratories (NYSE: BIO)

Thermo Fisher Scientific (NYSE: TMO)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 96% of the 143 members who have rated Harvard Bioscience so far believe the stock will outperform the S&P 500 going forward. These bulls include Notwage and All-Star JakilaTheHun, who is ranked in the top 0.1% of our community.

Earlier this month , Notwage listed several of Harvard Bioscience's positives:

"Rock solid fundamentals. Great industry with bright growth prospects in healthcare. Great margin of safety. Not covered by analysts. All in all a solid growth pick on sale."

Over the next five years, in fact, Harvard Bioscience is expected to grow its bottom line at a brisk rate of 25% annually. That's much faster than listed rivals Becton (9.9%), Bio-Rad (9.5%), and Thermo Fisher (12.1%).

CAPS All-Star JakilaTheHun elaborates on the Harvard Bioscience bull case:

Very well-run company, with great management, and an excellent track record of success. ROI is at 18% and ROE is at 23%. ... Not "cheap" per se, but about fairly valued right now. I can't claim to know much about this industry, but my green thumb for this one is a bet of management continuing to earn above-market returns on their investments.

What do you think about Harvard Bioscience -- or any other stock, for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!  

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Harvard Bioscience, Inc. Stock Quote
Harvard Bioscience, Inc.
$3.82 (6.41%) $0.23
Becton, Dickinson and Company Stock Quote
Becton, Dickinson and Company
$250.92 (3.45%) $8.38
Bio-Rad Laboratories, Inc. Stock Quote
Bio-Rad Laboratories, Inc.
$507.84 (0.45%) $2.26
Thermo Fisher Scientific Inc. Stock Quote
Thermo Fisher Scientific Inc.
$544.81 (0.78%) $4.21

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.